Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitura HealthASX:VIT -3.23% EV-to-EBIT is 11.66 as of Jul. 22, 2026, which is 72% above its 10-year median of 6.79. The stock has 8 warning signs investors should review. Among 689 Drug Manufacturers companies, Vitura Health ranks better than 62.99% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Vitura Health's Enterprise Value for the quarter that ended in Dec. 2025 was A$49.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vitura Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$2.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitura Health EV-to-EBIT Related Terms
Vitura Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Vitura Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitura Health EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vitura Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Vitura Health's EV-to-EBIT falls into.
Vitura Health's current Enterprise Value is A$28.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vitura Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$2.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitura Health (ASX:VIT) has a EV-to-EBIT of 11.66 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vitura Health and its competitors. This is 72% above median its historical median of 6.79. According to the industry distribution chart, Vitura Health ranks #255 out of 689 companies in the Drug Manufacturers industry, placing it in the top 37%.
Is Vitura Health's EV-to-EBIT too high?
Vitura Health's current EV-to-EBIT of 11.66 is 72% above median its 10-year median of 6.79. The Drug Manufacturers industry median EV-to-EBIT is 15.95. Vitura Health's value of 11.66 is 26.9% below this industry median. Based on the distribution chart, Vitura Health ranks #255 out of 689 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Vitura Health's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #255 out of 689 companies for EV-to-EBIT. This puts Vitura Health in the upper half of its industry. The industry median EV-to-EBIT is 15.95. Vitura Health's value of 11.66 is 26.9% below this benchmark. While the company's 10-year median is 6.79 vs. the industry median of 15.95, Vitura Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.95, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitura Health's current EV-to-EBIT of 11.66 is 26.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vitura Health and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitura Health's current EV-to-EBIT is 11.66, which is 72% above median its own 10-year median of 6.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.10, compared to a current price of A$0.03 — trading 70% below its estimated fair value. The current EV-to-EBIT is 11.66, which is 72% above median its 10-year median of 6.79 and 26.9% below the Drug Manufacturers industry median of 15.95. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current EV-to-EBIT is 11.66 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VIT has been successfully added to your 
